About Debiopharm
Debiopharm is a company based in Lausanne (Switzerland) founded in 1979.. Debiopharm has completed 1 acquisition, including Affinium Pharmaceuticals. Debiopharm offers products and services including Drug Development Services, Manufacturing Services, and Innovation Fund. Debiopharm operates in a competitive market with competitors including Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
- Headquarter Lausanne, Switzerland
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Debiopharm International
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
- Investors
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Debiopharm
Debiopharm offers a comprehensive portfolio of products and services, including Drug Development Services, Manufacturing Services, and Innovation Fund. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops compounds for oncology and infections through partnerships.
Produces drugs for development and commercialization processes.
Invests in digital health and smart data start-ups globally.
Funding Insights of Debiopharm
- Total Funding Total Funding
- Total Rounds 2
- Last Round Last Round
-
First Round
First Round
(14 May 2019)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2021 | Amount | Grant - Debiopharm | Valuation |
investors |
|
| May, 2019 | Amount | Grant - Debiopharm | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Debiopharm
Debiopharm has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include CARB-X. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Antibiotics, vaccines, and diagnostics against drug-resistant bacteria are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Debiopharm
Debiopharm has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Affinium Pharmaceuticals. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Canadian, clinical stage biopharma developing bacterial FAS II-inhibitors, highly specific to Staphylococcus sp. Acquired by Debiopharm
|
2000 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Debiopharm
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Debiopharm Comparisons
Competitors of Debiopharm
Debiopharm operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| domain | founded_year | HQ Location |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| domain | founded_year | HQ Location |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| domain | founded_year | HQ Location |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| domain | founded_year | HQ Location |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for the treatment of multiple disorders
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Debiopharm
When was Debiopharm founded?
Debiopharm was founded in 1979 and raised its 1st funding round 40 years after it was founded.
Where is Debiopharm located?
Debiopharm is headquartered in Lausanne, Switzerland. It is registered at Lausanne, Vaud, Switzerland.
What does Debiopharm do?
Biopharmaceutical company focused on oncology, infectious diseases, and orphan drugs. The lead drug candidates are Xevinapant for cancer, Afabicin for orthopedics, Alisporivir for cOVID and GI disorders, Debio 1450, ABSSSI, for staph infections.
Who are the top competitors of Debiopharm?
Debiopharm's top competitors include Merck, Roivant Sciences and AbbVie.
What products or services does Debiopharm offer?
Debiopharm offers Drug Development Services, Manufacturing Services, and Innovation Fund.
How many acquisitions has Debiopharm made?
Debiopharm has made 1 acquisition, including Affinium Pharmaceuticals.
Who are Debiopharm's investors?
Debiopharm has 1 investor. Key investors include CARB-X.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.